Prodotti competitors / Area Kite, Area Onco-Ema
Meeting highlights from the CHMP: Oncology - 7-10 November 2022
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On the 11th of November 2022, CHMP released its meeting highlights for the month of November. The main discussion points of the meeting included the following:
Recommendations on extensions of therapeutic indication
Enhertu (trastuzumab deruxtecan) - Daiichi Sankyo Europe GmbH
- Indication: a medicine used to treat breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery.
- Positive CHMP recommendation on extension of indications
Imfinzi (durvalumab) - AstraZeneca AB
- Indication: a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC).
- Positive CHMP recommendation on extension of indications
Lynparza (olaparib) - AstraZeneca AB
- Indication: a medicine used to treat adults who have advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene.
- Positive CHMP recommendation on extension of indications
Withdrawals of applications
Gavreto (pralsetinib) - Roche Registration GmbH
- Indication: a cancer medicine for treating adults with advanced non-small cell lung cancer caused by changes in a gene called RET (known as RET fusion-positive NSCLC) and who have not been treated with a RET inhibitor.
- Applications for extensions of therapeutic indications were withdrawn.
Febseltiq (infigratinib) - Helsinn Birex Pharmaceuticals Ltd
- Indication: treatment of cholangiocarcinoma.
- Applications for marketing authorisation were withdrawn.
Notification link: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022
Grazie per il tuo feedback!